Filing Overview
The provided filing is a Form 10-Q for Enochian Biosciences, Inc., not Lunai Bioworks Inc. It covers the three months ended September 30, 2020, compared with September 30, 2019. The request identifies the period as “2020 Q1”; the filing reflects Enochian’s fiscal first quarter. The financial statements are unaudited.
Business Context and Reporting Period
Enochian is a preclinical biotechnology company developing genetically modified cellular and immune-therapy technologies targeting HIV, hepatitis B, and certain cancers. The company has no commercial products or operating revenue and funds operations through equity and debt financing.
- Common shares outstanding at November 12, 2020: 46,636,976.
- Key development programs include ENOB-HV-01 for HIV and an HBV treatment licensed in January 2020.
- The company reported a June 2, 2020 FDA INTERACT meeting regarding ENOB-HV-01 and stated that management viewed the interaction as successful.
Financial Performance and Position
| Metric | Q1 FY2021 | Q1 FY2020 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Operating expenses | $2.859 million | $2.442 million | Up 17.0% |
| Research and development expense | $1.050 million | $0.520 million | Up 101.9% |
| General and administrative expense | $1.778 million | $1.901 million | Down 6.5% |
| Loss from operations | $2.859 million | $2.442 million | Higher loss |
| Net loss | $2.397 million | $4.083 million | Loss improved 41.3% |
| Basic and diluted loss per share | $0.05 loss | $0.09 loss | Improved |
| Net cash used in operating activities | $2.756 million | $1.801 million | Use increased |
Gross margin and operating margin are not meaningful because the company generated no revenue. The improvement in net loss primarily reflected a $2.369 million favorable year-over-year change in the fair value of contingent consideration, partly offset by higher research and development spending, interest expense, and the absence of a prior-year currency gain.
- Cash declined to $5.966 million at September 30, 2020 from $8.696 million at June 30, 2020.
- Working capital declined to $5.233 million from $7.606 million.
- Total assets were $175.133 million, including $154.824 million of indefinite-life license assets and $11.640 million of goodwill.
- Total liabilities were $10.903 million, including $1.200 million of convertible notes, $4.655 million of notes payable net of discount, $4.216 million of lease liabilities, and $2.755 million of contingent consideration.
- Stockholders’ equity was $164.230 million, compared with $166.272 million at June 30, 2020.
- The company had no investing cash outflows and no financing cash inflows during the quarter. Cash decreased by $2.731 million, including a $24,965 favorable currency translation effect.
Material Changes Versus the Prior Comparable Period
- R&D expense more than doubled, primarily because of $833,500 of payments under the HBV License Agreement, including scientific staffing and mouse studies. This increase was partly offset by the expiration of $300,000 of HIV license payments made in the prior-year period.
- Operating cash use increased by approximately $955,000, reflecting higher development spending and payments of prior-year accrued amounts.
- The contingent consideration liability decreased by $427,400 because of a fair-value adjustment, compared with a $1.942 million increase in the prior-year quarter.
- The company issued 139,567 shares to Lincoln Park Capital as a commitment fee but did not sell shares under the related equity purchase agreement during the quarter.
- Shares outstanding increased from 46,497,409 at June 30, 2020 to 46,636,976 at September 30, 2020.
- No material subsequent events were reported through November 12, 2020.
Guidance, Outlook, Risks and Unusual Items
- Management stated that it believed available liquidity and committed funds were sufficient to fund operations for the next twelve months. The filing does not provide a formal revenue, earnings, or cash-burn forecast.
- Additional capital may be required for equipment, the ENOB-HV-01 IND process, HIV programs, HBV development, and potential acquisitions. Financing may involve equity or debt and may be unavailable on acceptable terms, creating dilution and liquidity risk.
- The company expects no sales revenue until therapies or products receive regulatory approval and acknowledges that it may never become profitable.
- COVID-19 effects on operations, financial condition, liquidity, and capital resources could not be reasonably estimated as of the filing date.
- The company remains preclinical; its therapies require substantial development, regulatory approval, clinical validation, and market acceptance.
- Indefinite-life license assets and goodwill totaled $166.464 million. Management reported no impairment as of September 30, 2020, but adverse development or commercial outcomes could result in material impairment charges.
- The contingent consideration liability is a Level 3 fair-value measurement and is highly sensitive to stock price, volatility, and other valuation assumptions. Approximately 1,438,122 contingent shares remained issuable.
- Disclosure controls and procedures were deemed ineffective because of material weaknesses involving limited accounting resources, complex accounting issues, and inadequate segregation of duties. Management uses external consultants and expects deficiencies to continue until additional internal resources are available.
- The company disclosed related-party arrangements involving G-Tech and SRI, including the HBV License Agreement and related research payments.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Enochian Biosciences, Inc. rather than Lunai Bioworks Inc.
- Assess whether $5.966 million of cash and the Lincoln Park commitment are sufficient relative to the company’s approximately $2.756 million quarterly operating cash burn and planned development expenditures.
- Review the terms, maturity, interest, conversion rights, and discount accretion for the $1.200 million convertible notes and $4.655 million net note payable.
- Evaluate the regulatory and scientific status of ENOB-HV-01, the HBV program, and other preclinical candidates; the filing provides no assurance of clinical or commercial success.
- Monitor potential dilution from the Lincoln Park equity facility, 1.438 million contingent shares, outstanding warrants, options, and restricted stock units.
- Review the material weaknesses in internal control and whether remediation has occurred in subsequent filings.
- Test the carrying values of the $154.824 million license asset and $11.640 million goodwill against updated development and impairment assumptions.